Thryv Therapeutics Inc., a clinical-stage biotechnology company, announced that Dr. Saumya Das will present compelling new preclinical results on its lead compound, THRV-1268, at the upcoming European Society of Cardiology (ESC) Congress 2025, taking place August 29 – September 1, 2025, in Madrid, Spain. The presentations will showcase breakthrough findings that strengthen the scientific case for SGK1 inhibition as a powerful strategy against inflammation and fibrosis-driven cardiac remodeling.
Novel SGK1 Inhibitor Shows Superior Cardiac Benefits
THRV-1268 is a best-in-class, highly selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitor with the potential to transform the treatment landscape for Long QT Syndrome (LQTS), heart failure, and atrial fibrillation—three serious cardiac conditions with urgent unmet medical needs.
Thryv's presentation will spotlight results from a Transaortic Constriction (TAC) preclinical model with both THRV-1268 and Jardiance® (empagliflozin) – an SGLT2 inhibitor currently used as part of guideline directed medical therapy for individuals with heart failure. These breakthrough findings for both SGK1 monotherapy and in combination with SGLT2i inhibition demonstrate critical pathways in heart failure and related disorders.
Collaborative Research Validates SGK1 Target in Long QT Syndrome
In addition to Thryv's data presentation, research conducted by the European Joint Programme on Rare Diseases (EJPRD) will also be featured at ESC 2025. The collaborative research with one of Thryv's SGK1 inhibitors provides extensive evidence for the role of SGK1 inhibition in Long QT Syndrome (LQTS), through its effect on late sodium current and action potential duration in preclinical models of LQTS.
Key Presentation Details
Thryv's Heart Failure Research:
- Title: "THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure"
- Presenter: Saumya Das, MD, PHD, Co-Director, Resynchronization and Advanced Cardiac Therapeutics Program, Massachusetts General Hospital
- Date: Saturday, August 30, 2025
- Time: 1:15 – 2:00 p.m. CET
- Location: Station 4 (Research Gateway)
- Format: Moderated e-Poster
EJPRD's Long QT Syndrome Research:
- Title: "SGK1 inhibition shortens action potential duration and exerts anti-arrhythmic effects in LQT3 mice and LQT2 rabbits by reducing enhanced late sodium current"
- Presenter: Simona Casini, Amsterdam University Medical Centre (AUMC)
- Date: Sunday, August 31, 2025
- Time: 1:25 – 2:15 p.m. CET
- Location: Science Box 4 (Research Gateway)
- Format: Abstract Session
Targeting Critical Cardiac Pathways
Thryv Therapeutics is advancing a series of potent and selective SGK1 inhibitors that target the underlying causes of electrical and structural remodelling which leads to cardiac conditions such as Long QT Syndrome, heart failure, and atrial fibrillation.
In cardiometabolic diseases, SGK1 plays a critical role in driving pathological processes, including inflammation, structural remodeling, electrical remodeling and fibrosis, which can play a significant role in the development of heart failure and atrial fibrillation.
About the Company
Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat Long QT Syndrome, heart failure and atrial fibrillation with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).
